Product Overview Product feature summary

• • This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories.
• • This product has been authorized only for the detection and differentiation of nucleic acid from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), not for any other viruses or pathogens.
• • The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
• • This test is authorized for the qualitative detection and differentiation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A virus, influenza B virus and respiratory syncytial virus (RSV) RNA in anterior nasal (nasal) swab and nasopharyngeal swab specimens collected from individuals with signs and symptoms of respiratory tract infection consistent with COVID-19 by their healthcare provider.

Specifications Product specifications and dimensions

• Additional Attributes
  EUA
• Brand
  Cobas
• Item
  Quality Control Kit
• Item Type
  SARS-CoV-2/Influenza A & B/RSV Test
• Level
  Positive/Negative
• Packaging
  Set of 3
• Quantity
  6/Kit

Catalog Description As seen in our print catalog

This nucleic acid test, for use on the cobas liat system, is an automated, rapid multiplex real-time reverse transcription polymerase chain reaction (RT-PCR) test intended for the simultaneous qualitative detection and differentiation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) RNA in 20 minutes from a single nasal and nasopharyngeal sample in just 1 test.